MOSAIC is heading to Lima, Peru, for the HIV Research for Prevention Conference (HIVR4P 2024). We invite conference attendees to join us for the following sessions.
Continue Reading
Category: Research
CATALYST’S QUALITY IMPROVEMENT COLLABORATIVE
For the first time, with the PrEP ring and CAB PrEP entering markets alongside oral PrEP, women have multiple HIV prevention methods to choose from. Now prevention programs face another first: how to deliver those options in ways that ensure informed choice and foster effective use. To help answer that question, MOSAIC embedded a quality improvement collaborative into its flagship CATALYST study.
Continue Reading
NEW DATA, NEW OPPORTUNITIES: THE EXPANDING EVIDENCE BASE FOR THE PrEP RING
Three MTN studies – REACH, DELIVER, and B-PROTECTED – recently published critical new data on PrEP ring use among adolescent girls and young women (AGYW), pregnant individuals, and breastfeeding individuals in Africa. All studies offer compelling evidence that the ring is safe for use among these populations.
Continue Reading
INNOVATION KEY TO SUSTAINING IMPACT OF U.S. GOVERNMENT’S INVESTMENTS IN GLOBAL HIV RESPONSE
The world is closer than ever to ending HIV as a public health threat. As the global response to the HIV epidemic continues to transition from an emergency response to one focused on sustaining the progress we’ve made, it is critical that we continue to find innovative solutions to address new challenges.
Continue Reading
BEYOND ENGAGEMENT: BRINGING THE POWER OF YOUNG PEOPLE TO PrEP RESEARCH AND PROGRAMS
Expanding access to and uptake of PrEP products among young people, especially adolescent girls and young women, will be key to ending the HIV epidemic. But how do we ensure HIV prevention efforts resonate with and are effective for young millennials and Gen Z? What does meaningful youth engagement in PrEP delivery really mean?
Continue Reading
YOUTH-POWERED: THREE WAYS THE CATALYST STUDY ENGAGES YOUNG WOMEN TO UNDERSTAND PrEP CHOICE
What sets CATALYST apart is the study’s emphasis on meaningful involvement of young people at every stage of the research to understand end-user perspectives and help tailor the study to meet their needs. This makes us hopeful because the inclusion of young people in the CATALYST journey has not been tokenistic; rather our contributions have been reflected in the whole process so far. In this post, we describe three ways youth have been engaged in CATALYST.
Continue Reading
THE CATALYST STUDY: CATALYZING ACCESS TO NEW PREVENTION PRODUCTS TO STOP HIV
We are excited to announce the launch of Catalyzing Access to New Prevention Products to Stop HIV (CATALYST), MOSAIC’s flagship product introduction study. CATALYST will provide and assess an enhanced service delivery package that includes oral PrEP, the PrEP ring, and injectable cabotegravir for PrEP.
Continue Reading
THE FUTURE OF PrEP: IMPLEMENTATION STUDIES TO GUIDE THE ROLLOUT OF NEW PrEP PRODUCTS
As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.
Continue Reading
CONFERENCE REFLECTIONS: TWO CROI “ROOKIES” DRAW INSPIRATION FROM CROI AT 30
CROI is a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases, including HIV and AIDS. It was the 30th year of the conference, but our first time attending. In this post, we reflect on what we learned and how we might apply key takeaways to our work on MOSAIC.
Continue Reading
A NEW OPTION TO TRANSFORM HIV PREVENTION
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading